Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$20.38 USD
-0.09 (-0.44%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $20.38 0.00 (0.00%) 7:18 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Balance Sheet
Fiscal Year End for Catalyst Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 138 | 298 | 191 | 140 | 95 |
Receivables | 54 | 10 | 7 | 6 | 11 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 16 | 7 | 8 | 5 | 2 |
Other Current Assets | 13 | 5 | 4 | 8 | 4 |
Total Current Assets | 219 | 321 | 210 | 159 | 111 |
Net Property & Equipment | 1 | 1 | 1 | 0 | 0 |
Investments & Advances | 16 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 37 | 19 | 24 | 33 | 0 |
Intangibles | 194 | 32 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 470 | 376 | 238 | 192 | 112 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 15 | 4 | 3 | 4 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 61 | 54 | 24 | 19 | 20 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 76 | 58 | 27 | 23 | 24 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 3 | 14 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 82 | 75 | 31 | 23 | 25 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 266 | 250 | 233 | 223 | 216 |
Retained Earnings | 121 | 50 | -26 | -54 | -129 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 388 | 300 | 207 | 170 | 88 |
Total Liabilities & Shareholder's Equity | 470 | 376 | 238 | 192 | 112 |
Total Common Equity | 388 | 300 | 207 | 170 | 88 |
Shares Outstanding | 117.50 | 104.00 | 103.10 | 103.60 | 103.00 |
Book Value Per Share | 3.30 | 2.89 | 2.01 | 1.64 | 0.85 |
Fiscal Year End for Catalyst Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 376 | 310 | 138 | 121 | 179 |
Receivables | 57 | 60 | 54 | 48 | 43 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 18 | 20 | 16 | 9 | 11 |
Other Current Assets | 24 | 14 | 13 | 14 | 9 |
Total Current Assets | 474 | 405 | 219 | 192 | 241 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 13 | 15 | 16 | 13 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 40 | 38 | 37 | 37 | 23 |
Intangibles | 175 | 185 | 194 | 167 | 176 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 706 | 647 | 470 | 413 | 444 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 10 | 15 | 5 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 85 | 69 | 61 | 53 | 48 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 92 | 80 | 76 | 58 | 53 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 3 | 4 | 13 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 98 | 85 | 82 | 65 | 69 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 423 | 417 | 266 | 262 | 258 |
Retained Earnings | 185 | 145 | 121 | 86 | 117 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 609 | 561 | 388 | 349 | 375 |
Total Liabilities & Shareholder's Equity | 706 | 647 | 470 | 413 | 444 |
Total Common Equity | 609 | 561 | 388 | 349 | 375 |
Shares Outstanding | 118.10 | 118.00 | 117.50 | 106.50 | 106.50 |
Book Value Per Share | 5.15 | 4.76 | 3.30 | 3.27 | 3.52 |